Depression and renal disease

Seminars in Dialysis

Volumn 18, Issue 2, 2005, Pages 73-81

  Tossani, Eliana ^a   Cassano, Paolo ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMOXAPINE; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; ISOCARBOXAZID; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; ANOREXIA; ANXIETY; APATHY; CANCER; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EJACULATION DISORDER; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; KIDNEY DISEASE; LETHALITY; LIBIDO DISORDER; LIVER TOXICITY; LOW DRUG DOSE; MAJOR DEPRESSION; MIGRAINE; MORTALITY; NAUSEA; NERVOUSNESS; ORGASM DISORDER; ORTHOSTATIC HYPERTENSION; PATIENT COMPLIANCE; PREVALENCE; PRIAPISM; PROGNOSIS; QT PROLONGATION; QUALITY OF LIFE; RASH; RECURRENT DISEASE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STROKE; SWEATING; TACHYCARDIA; TOXICITY; TREATMENT OUTCOME; URINE RETENTION; VISUAL DISORDER; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; KIDNEY FAILURE, CHRONIC; MONOAMINE OXIDASE INHIBITORS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-2; SEROTONIN ANTAGONISTS;

EID: 17144403424     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18217.x     Document Type: Review

References (109)

1. Cassano P, Fava M: Depression and public health: an overview. J Psychosom Res 52:1-9, 2002
2. Lepine JP, Gastpar M, Mendlewicz J, Tylee A: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19-29, 1997
3. Sheikh J, Cassidy EL, Doraiswamy PM, Salomon RM, Hornig M, Holland P, Mandel FS, Clary CM, Burt T: Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc 52:86-92, 2004
4. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19, 1994
5. Blazer DG, Kessler RC, McGonagle KA, Swartz MS: The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 151:979-986, 1994
6. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: National Comorbidity Survey Replication. The epidemiology of major depressive disorder results from the National Comorbidity Survey Replication (NCS-R). JAMA 18:3095-3105, 2003
7. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J: The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 18:914-919, 1989
8. Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C, Fava M: The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 160:2122-2127, 2003
9. Wulsin LR, Vaillant GE, Wells VE: A systematic review of the mortality of depression. Psychosom Med 61:6-17, 1999
10. Zheng D, Macera CA, Croft JB, Giles WH, Davis D, Scott WK: Major depression and all-cause mortality among white adults in the United States. Ann Epidemiol 7:213-218, 1997
11. Bergen AW, Caporaso N: Cigarette smoking. J Natl Cancer Inst 91:1365-1375, 1999
12. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman JM, Marek RG, Maurer TA, Meyer R, Phillips K, Ross J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ: The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277:333-340, 1997
13. Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annn ML: Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 55:171-178, 1999
14. Lesage AD, Boyer R, Grunberg F, Vanier C, Morissette R, Menard-Buteau C, Loyer M: Suicide and mental disorders: a case-control study of young men. Am J Psychiatry 151:1063-1068, 1994
15. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994
16. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462-1470, 2000
17. Scoot J: Treatment of chronic depression. N Engl J Med 342:1518-1520, 2000
18. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF: Major depressive subtypes and treatment response. Biol Psychiatry 42:568-576, 1997
19. Fava M: Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 63:305-307, 2002
20. Simon GE, VonKorff M, Picinelli M, Fullerton C, Ormel J: An international study of the relation between somatic symptoms and depression. N Engl J Med 341:1329-1335, 1999
21. Gerber PD, Barrett JE, Barrett JA, Oxman TE, Manheimer E, Smith R, Whiting RD: The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med 7:170-173, 1992
22. Kroenke K, Spitzer RL, Williams JB, Linzer M, Hahn SR, deGruy FV 3rd, Brody D: Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med 3:774-779, 1994
23. Coyne JC, Schwenk TL, Fechner-Bates S: Nondetection of depression by primary care physicians reconsidered. Gen Hosp Psychiatry 17:3-12, 1995
24. Anderson RJ, Freeland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24:1069-1078, 2001
25. Brown WA, Harrison W: Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 56:30-34, 1995
26. Fava M, Rosenbaum JF: Pharmacotherapy and somatic therapies. In: Beckman EE, Leber WR, eds. Handhook of Depression. New York: Guilford Press, 1995:280-301
27. Frazer A: Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psvchiatry 62(suppl 12):16-23, 2001
28. Masand PS, Gupta S: Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 7:69-84, 1999
29. Lane RM: SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 12:192-214, 1998
30. Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, Sundell KL, Michelson D, Beasley CM Jr: Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 60:389-394, 1999
31. Fava M, Kendler KS: Major depressive disorder. Neuron 28:335-341, 2000
32. Cassano P, Fava M: Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 16:15-25, 2004
33. Massana J, Moller HJ, Burrows GD, Montenegro RM: Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 14:73-80, 1999
34. Scates AC, Doraiswamy PM: Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 34:1302-1312, 2000
35. Schatzberg AF: Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 1(suppl 10):31-38, 2000
36. Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205-222, 2004
37. Chouinard G, Annable L, Bradwejn J: An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83:126-128, 1984
38. Stahl SM: "Awakening" from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. J Clin Psychiatry 58:381-382, 1997
39. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW: Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 154:125-134, 1988
40. Nelson JC, Mazure CM, Bowers MB, Jatlow PI: A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307, 1991
41. Nelson JC: Combined drug treatments; pros and cons. In: Syllabus and Proceedings Summary of the 1999 Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1999:227
42. Thase ME: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59:502-508, 1998
43. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315, 2002
44. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401, 1995
45. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA: A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21:643-658, 1999
46. Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB: Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63:181-186, 2002
47. Hellerstein DJ, Batchelder S, Kreditor D, Fedak M: Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. J Clin Psychopharmacol 21:325-329, 2001
48. Feighner JP: Mechanism of action of antidepressant medications. J Clin Psychiatry 60(suppl 4):4-11, 1999
49. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53:608-636, 1997
50. Stewart DE: Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 47:375-377, 2002
51. Mazur A, Strasberg B, Kusniec J, Sclarovsky S: QT prolongation and polymorphous ventricular tachycardia associated with trazodone-amiodarone combination. Int J Cardiol 52:27-29, 1995
52. Saenz de Tejada I, Ware JC, Blanco R, Pittard JT, Nadig PW, Azadzoi KM, Krane RJ, Goldstein I: Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 145:60-64, 1991
53. Clark NA, Alexander B: Increased rate of trazodone prescribing with bupropion and selective serotonin-reuptake inhibitors versus tricyclic antidepressants. Ann Pharmacother 34:1007-1012, 2000
54. Richelson E: Pharmacology of antidepressants. Mayo Clin Proc 76:511-527, 2001
55. Holm KJ, Markham A: Mirtazapine: a review of its use in major depression. Drugs 57:607-631, 1999
56. Carpenter LL, Yasmin S, Price LH: A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183-188, 2002
57. Pletscher A: The discovery of antidepressants: a winding path. Experientia 47:4-8, 1991
58. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, Nunes E, Harrison W, Klein DF: Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 21:30-34, 1993
59. Paykel ES, Parker RR, Penrose RJ, Rassaby ER: Depressive classification and prediction of response to phenelzine. Br J Psychiatry 134:572-581, 1979
60. Richelson E: Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc 69:1069-1081, 1994
61. Katon WJ: The Institute of Medicine "Chasm" report: implications for depression collaborative care models. Gen Hosp Psychiatry 25:222-229, 2003
62. Wells KB, Sturm R, Sherbourne CD, Meredith LS: Caring for Depression. Cambridge, MA: Harvard University Press, 1996
63. Lecrubier Y: Prescribing patterns for depression and anxiety worldwide. J Clin Psychiatry 62(suppl 13):31-36, 2001
64. Patten S: Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord 63:35-41, 2001
65. Konsman JP, Parnet P, Dantzer R: Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25:154-159, 2002
66. Cohen-Cole SA, Kaufman KG: Major depression in physical illness: diagnosis, prevalence, and antidepressant treatment (a ten year review: 1982-1992). Depression 1:181-204, 1993
67. Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: diagnosis, biology and treatment. Arch Gen Psychiatry 55:580-592, 1998
68. Lesperance F, Frasure-Smith N: Depression in patients with cardiac disease: a practical review. J Psychosom Res 48:379-391, 2000
69. Gavard JA, Lustman PJ, Clouse RE: Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 16:1167-1178, 1993
70. Khaodhiar L, McCowen KC, Blackburn GL: Obesity and its comorbid conditions. Clin Cornerstone 2:17-31, 1999
71. McDonald WM, Richard IH, DeLong MR: Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54:363-375, 2003
72. Lee HB, Lyketsos CG: Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry 54:353-362, 2003
73. Haase CG, Tinnefeld M, Lienemann M, Ganz RE, Faustmann PM: Depression and cognitive impairment in disability-free early multiple sclerosis. Behav Neurol 14:39-45, 2003
74. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, van Tilburg W: Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58:221-227, 2001
75. Pirl WF, Roth AJ: Diagnosis and treatment of depression in cancer patients. Oncology (Huntingt) 13:1293-1301, 1999
76. Lustman PJ, Griffith LS, Freedland KE, Clouse RE: The course of major depression in diabetes. Gen Hosp Psychiatry 19:138-143, 1997
77. Mischoulon D, McColl R, Howarth S, Lagomasino IT, Alpert JE, Nierenberg AA, Fava M: Management of major depression in the primary care setting. Psychotherapy Psychosom 70:103-107, 2001
78. Mulrow CD, Williams JW Jr, Chiquette E, Aguilar C, Hitchcock-Noel P, Lee S, Cornell J, Stamm K: Efficacy of newer medications for treating depression in primary care patients. Am J Med 108:54-64, 2000
79. Anderson IM, Tomenson BM: Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310:1433-1438, 1995
80. Rosal MC, Ockene JK, Ma Y, Hebert JR, Merriam PA, Matthews CE, Ockene IS: Behavioral risk factors among members of a health maintenance organization. Prev Med 33:586-594, 2001
81. Aneshensel C, Huba G: Depression, alcohol use, and smoking over one year: a four-wave longitudinal causal model. J Abnorm Psychol 92:1134-1150, 1983
82. Katon W, von Korff M, Lin E, Bush T, Ormel J: Adequacy and duration of antidepressant treatment in primary care. Med Care 30:67-76, 1992
83. Simon GE, VonKorff M, Wagner EH, Barlow W: Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 15:399-408, 1993
84. Lederbogen F, Gilles M, Maras A, Hamann B, Colla M, Heuser I, Deuschle M: Increased platelet aggregability in major depression? Psychiatry Res 102:255-261, 2001
85. Winokur A, Maislin G, Phillips JL, Amsterdam JD: Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 145:325-330, 1988
86. Leonard BE: Changes in the immune system in depression and dementia: causal or co-incidental effects? Int J Dev Neurosci 19:305-312, 2001
87. Greenstein S, Siegal B: Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation 66:1718-1726, 1998
88. Dimatteo MR, Lepper HS, Croghan TW: Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101-2107, 2000
89. Finkelstein FO, Finkelstein SH: Depression in chronic dialysis patients: assessment and treatment. Nephrol Dial Transplant 15:1911-1913, 2000
90. Kimmel PL: Psychosocial factors in dialysis patients. Kidney Int 59:1599-1613, 2001
91. Kim JA, Lee YK, Huh WS, Kim YG, Kim DJ, Oh HY, Kang SA, Kim Moon YH, Kim HW, Kim JH: Analysis of depression in continuous ambulatory peritoneal dialysis patients. J Korean Med Sci 17(6):790-794, 2002
92. Wuerth D, Finkelstein SH, Kliger AS, Finkelstein FO: Chronic peritoneal dialysis patients diagnosed with clinical depression, results of pharmacological therapy. Semin Dial 16:424-427, 2003
93. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis H: Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 57:2093-2098, 2000
94. Beliles KE, Stoudemire A: Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 39:S2-S19, 1998
95. Abbey SE, Kennedy SH, Kaplan AS, Toner BB, Garfinkel PE: Self-report symptoms that predict major depression in patients with prominent physical symptoms. Int J Psychol Med 20:247-258, 1990
96. McEvoy G, ed. AHFS drug information 2000. Bethesda, MD: American Society of Health-System Pharmacists, 2000
97. Whooley MA, Simon GE: Managing depression in medical outpatients. N Engl J Med 343:1942-1950, 2000
98. Kennedy SH, Craven JL, Roin GM: Major depression in renal dialysis patients: an open trial of antidepressant therapy. J Clin Psychiatry 50:60-63, 1989
99. Streltzer J: Diagnosis and treatment consideration in depressed dialysis patients. Clin Exp Dial Apheresis 7:254-257, 1983
100. Wuerth DW, Finkelstein SH, Ciarica J, Peterson R, Kliger AS, Finkelstein FO: Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis 37:1011-1017, 2001
101. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM: Drug Prescribing in Renal Failure, 4th ed. Philadelphia, PA: American College of Physicians, 1999
102. Lieberman JA: Tricyclic antidepressants and metabolite levels in chronic renal failure. Clin Pharmacol Ther 37:301-307, 1985
103. Dawling S, Lynn K, Rosser R, Braithwaite R: The pharmacokinetics of nortriptyline in patients with chronic renal failure. Br J Clin Pharmacol 12:39-45, 1981
104. Haffke EA, Rajendran S, Egan JD: Dialysis, depression and antidepressants. J Clin Psychiatry 39:759, 1978
105. Schrier MD, Gambertoglio JG: Handbook of Drug Therapy in Liver and Kidney Disease. Boston: Little, Brown, 1991
106. Fitton A, Faulds D, Goa KL: Moclobemide: a review of its pharmacological proprieties an therapeutic use in depressive illness. Drugs 43:561-596, 1992
107. Gelman CR, Rumack BH, Hutchinson TA, eds. Drugdex® System. Englewood, CO: Micromedex Inc, 1998
108. Bazire S: Psychotropic drug directory. London: Quay Books Division, Mark Allen Publishing, 1996
109. Rosenstein D, Soleymani K, Cai J: Chronic depression in patients with medical illness. In: Alpert JE, Fava M (eds). Handbook of Chronic Depression, Dekker, New York, 2003